
Women's health venture funding fell to $1.58 billion in 2025
SVB's 2026 investment report shows a steep slide from the 2024 record — and a striking valuation premium for AI-focused startups.
Reporting on guideline revisions, drug approvals, safety warnings and newly published studies affecting women's care, each traced to the source document.

SVB's 2026 investment report shows a steep slide from the 2024 record — and a striking valuation premium for AI-focused startups.

On May 1, 2026, the Fifth Circuit reinstated in-person dispensing for mifepristone; the order had not taken effect as of mid-May.

New federal guidance issued in March 2026 forced safety-net contraceptive providers through a compressed reapplication cycle.

A February 2026 FDA label update and new REMS program changed who can insert and remove the contraceptive implant.

The final federal count, published March 4, 2026, shows 649 maternal deaths and a rate statistically unchanged from 2023.

Congress's November 2025 appropriations law preserved the fruit and vegetable benefit that a budget proposal had threatened to cut.